Evidence map›Paper›PMID 40185824›Full record

Trial reportScientific reports2025

Long-term gamma-aminobutyric acid (GABA) treatment fails to regain beta-cell function in longstanding type 1 diabetes in a randomized trial.

Henrik Hill, Per Lundkvist, Georgios Tsatsaris, Bryndis Birnir, Daniel Espes, Per-Ola Carlsson

Abstract readRandomized Controlled TrialClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Review
  3. Peripheral GABA Signaling in Metabolic Adaptation and Maladaptation.International journal of molecular sciences · 2026
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Henrik HillDepartment of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Per LundkvistDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Georgios TsatsarisDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Bryndis BirnirDepartment of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
Daniel EspesDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Per-Ola CarlssonDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden. per-ola.carlsson@mcb.uu.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gamma-amino butyric acid (GABA) has in experimental studies been found to promote beta-cell proliferation, enhance insulin secretion and reduce inflammation, positioning it as a candidate drug for type 1 diabetes (T1D) therapy. This phase I/II randomized controlled trial assessed the safety and efficacy of long-term treatment with Remygen

Indexed as

Diabetes Mellitus, Type 1gamma-Aminobutyric AcidInsulin-Secreting CellsAdultBlood GlucoseC-PeptideHumansInsulinMaleMiddle AgedBlood GlucoseC-Peptidegamma-Aminobutyric AcidInsulinBeta-CellGABAOral therapyRegenerative therapyType 1 diabetes

Identifiers

PMID40185824
PMCPMC11971400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.